KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Receivables: 2009-2025

Historic Receivables for Arbutus Biopharma (ABUS) over the last 16 years, with Sep 2025 value amounting to $905,000.

  • Arbutus Biopharma's Receivables fell 43.72% to $905,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 24.27%. This contributed to the annual value of $2.4 million for FY2024, which is 35.64% up from last year.
  • As of Q3 2025, Arbutus Biopharma's Receivables stood at $905,000, which was down 11.71% from $1.0 million recorded in Q2 2025.
  • Arbutus Biopharma's Receivables' 5-year high stood at $2.7 million during Q1 2023, with a 5-year trough of $899,000 in Q4 2021.
  • In the last 3 years, Arbutus Biopharma's Receivables had a median value of $1.8 million in 2023 and averaged $1.8 million.
  • Per our database at Business Quant, Arbutus Biopharma's Receivables spiked by 102.89% in 2023 and then crashed by 44.74% in 2025.
  • Over the past 5 years, Arbutus Biopharma's Receivables (Quarterly) stood at $899,000 in 2021, then skyrocketed by 50.39% to $1.4 million in 2022, then soared by 31.36% to $1.8 million in 2023, then soared by 35.64% to $2.4 million in 2024, then slumped by 43.72% to $905,000 in 2025.
  • Its last three reported values are $905,000 in Q3 2025, $1.0 million for Q2 2025, and $1.2 million during Q1 2025.